33007-09-9

Usage

Uses

Used in Pharmaceutical Industry:
Furo[3,2-c]pyridin-4-amine is utilized as a potential drug candidate for its antitumor properties, targeting various types of cancer cells and contributing to the development of novel therapeutic agents.
Used in Antiviral Applications:
Furo[3,2-c]pyridin-4-amine is employed as an antiviral agent, leveraging its ability to inhibit viral replication and reduce the spread of infections, thereby offering potential treatments for viral diseases.
Used in Antimicrobial Applications:
Furo[3,2-c]pyridin-4-amine is used as an antimicrobial agent, effective against a range of bacteria and other microorganisms, which can lead to the creation of new antibiotics and antifungal medications.
Used in Organic Synthesis:
Furo[3,2-c]pyridin-4-amine serves as a precursor in the synthesis of various organic compounds, playing a crucial role in the development of new chemical entities with diverse applications in different industries.

Upstream product

• 33007-16-8 4-hydrazinylfuro[3,2-c]pyridine 
• 31270-80-1 4-chlorofuro[3,2-c]pyridine 
• 33007-15-7 7-hydroxy-6,7-dihydro-5H-furo[3,2-c]pyridin-4-one 
• 26956-43-4 5H-furo[3,2-c]pyridin-4-one 
• 46265-05-8 2-(2-amino-1-hydroxy-ethyl)-furan-3-carboxylic acid ethyl ester 
• 26956-43-4 furo[3,2-c]pyridine-4-ol 

Downstream Products

• 215453-73-9 N-(furo[3,2-c]pyridin-4-yl)benzamide 
• 252970-97-1 2-amino-3-(4-amino-furo[3,2-c]pyridin-2-yl)-propionic acid methyl ester 
• 252970-82-4 β-[2-(4-aminofuro[3,2-c]pyridine)]alanine 
• 215453-74-0 N-(2-hydroxymethyl-furo[3,2-c]pyridin-4-yl)-benzamide 
• 252971-09-8 3-(4-amino-furo[3,2-c]pyridin-2-yl)-2-tert-butoxycarbonylamino-propionic acid 
• 252971-51-0 [1-(4-amino-furo[3,2-c]pyridin-2-ylmethyl)-2-(4-methyl-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 215453-79-5 3-(4-amino-furo[3,2-c]pyridin-2-yl)-2-(7-methoxy-naphthalene-2-sulfonylamino)-propionic acid methyl ester 
• 215453-75-1 2-(4-benzoylamino-furo[3,2-c]pyridin-2-ylmethyl)-2-tert-butoxycarbonylamino-malonic acid diethyl ester 
• 184913-10-8 2-(2-methylphenyl)imidazo[2,1-a]isoquinoline 
• 1192807-40-1 (2R)-N-{furo[3,2-c]pyridin-4-yl}-3'H-4-azaspiro[bicyclo[2.2.2]octane-2,2'-[1,4]oxazole]-5'-amine 
• 1309048-39-2 N-{2-[3,5-dicyano-1,2,6-trimethyl-1,4-dihydropyridin-4-yl]furo[3,2-c]pyridin-4-yl}benzamide 
• 1309048-36-9 N-[2-(3-cyano-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridin-4-yl)furo[3,2-c]pyridin-4-yl]benzamide 
• 1309048-35-8 N-[2-(5-cyano-3,6-dimethyl-4,7-dihydro[1,2]oxazolo[5,4-b]pyridin-4-yl)furo[3,2-c]pyridin-4-yl]benzamide 
• 1309048-34-7 N-[2-(7,9-dicyano-6-methyl-1,3,4,8-tetrahydropyrido[2,1-c][1,4]oxazin-8-yl)furo[3,2-c]pyridin-4-yl]benzamide 

Relevant academic research and scientific papers

AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF

This invention relates to novel 4-(furo[3,2-c]pyridin-2-yl)-l,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

Heterocyclic derivatives and their use as antithrombotic agents

The present invention relates to antithrombotic compounds comprising the group Q, Q having formula (I), wherein the substructure (i) is a structure selected from (a, b and c), wherein X is O or S; X′ being independently CH or N; and m is 0, 1, 2 or 3; wherein the group Q is bound through an oxygen atom or an optionally substituted nitrogen or carbon atom, or a pharmaceutically acceptable salt thereof or a prodrug thereof. The compounds of the invention are therapeutically active and in particular are antithrombotic agents.

Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors

Replacement of the highly basic benzamidine moiety with moderate basic amino-bicycloaryl moieties in a series of thrombin inhibitors related to NAPAMP provided potent enzyme inhibition and significant improvements in membrane transport and oral bioavailability.